Questions and Answers on Adstiladrin | Gene Therapy for BCG Unresponsive NMIBC
In the second part of the presentation, Dr. Colin Dinney, principal investigator on the clinical trials that led to this approval of Adstiladrin, answers the most commonly asked questions about this novel therapy.
Пікірлер